{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:04:12Z","timestamp":1790507052865,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurg.","NEUROS"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>\n                      The importance of the O\n                      <jats:sup>6<\/jats:sup>\n                      -methylguanine-DNA methyltransferase (MGMT) promoter methylation status as a predictive factor for the response to chemotherapy with temozolomide is well established. Its significance though at stratifying glioblastoma (GBM) patients in regard to their prognostic factors and the impact of surgical approach on them has not been identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To reveal possible differences in the prognostic factors and the impact of surgery between GBM patients stratified according to their MGMT status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The authors retrospectively analyzed 186 patients with a newly diagnosed primary supratentorial GBM treated with surgical resection followed by standard radiation and chemotherapy. A prospective quantitative volumetric analysis of tumor characteristics identified on magnetic resonance imaging was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      For the 109 patients with unmethylated MGMT promoter, extent of resection (EOR) represented independent predictor of survival, whereas residual tumor volume (RTV), Karnofsky Performance Score, and age were found to be independent prognostic factors of survival for the 77 patients with methylated MGMT promoter. For the group of patients with unmethylated and the group with methylated MGMT promoter, an EOR threshold of 70% and 98% and an RTV threshold of 1.5 and 1 cm\n                      <jats:sup>3<\/jats:sup>\n                      were identified, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The selection of patients according to the MGMT promoter methylation status resulted in different prognostic factors and different resection thresholds for each patient population. A survival benefit seen from 70% EOR threshold in patients with MGMT unmethylated GBM supports the doctrine of maximum safe resection rather than the \u201call-or-nothing\u201d approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuros\/nyaa562","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T15:09:35Z","timestamp":1607180975000},"page":"E323-E329","source":"Crossref","is-referenced-by-count":30,"title":["MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold"],"prefix":"10.1227","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-7359","authenticated-orcid":false,"given":"Sotirios","family":"Katsigiannis","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Knappschaftskrankenhaus University Hospital of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-527X","authenticated-orcid":false,"given":"Stefan","family":"Grau","sequence":"additional","affiliation":[{"name":"Center for Neurosurgery, Department of General Neurosurgery, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Krischek","sequence":"additional","affiliation":[{"name":"Center for Neurosurgery, Department of General Neurosurgery, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Er","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Knappschaftskrankenhaus University Hospital of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Pintea","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Bergmannsheil University Hospital of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Goldbrunner","sequence":"additional","affiliation":[{"name":"Center for Neurosurgery, Department of General Neurosurgery, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Stavrinou","sequence":"additional","affiliation":[{"name":"Center for Neurosurgery, Department of General Neurosurgery, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4]]},"reference":[{"issue":"Suppl_5","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol"},{"issue":"Suppl 3","key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","article-title":"High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Stupp","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2176\/nmc.50.713","article-title":"Standard therapy for glioblastoma\u2014a review of where we are","volume":"50","author":"Nishikawa","year":"2010","journal-title":"Neurol Med Chir"},{"issue":"3","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3322\/caac.20069","article-title":"Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma","volume":"60","author":"Van Meir","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"issue":"6 Suppl 19","key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2003.11.031","article-title":"Factors influencing survival in high-grade gliomas","volume":"30","author":"Buckner","year":"2003","journal-title":"Semin Oncol"},{"issue":"10","key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"bib10-20231011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3171\/jns.2003.99.3.0467","article-title":"Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project","volume":"99","author":"Laws","year":"2003","journal-title":"J Neurosurg"},{"issue":"4","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3171\/2015.5.JNS142087","article-title":"The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection","volume":"124","author":"Li","year":"2016","journal-title":"J Neurosurg"},{"issue":"1","key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3171\/2008.4.17536","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt","year":"2009","journal-title":"J Neurosurg"},{"issue":"7","key":"bib13-20231011","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"bib15-20231011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nop020","article-title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera","year":"2010","journal-title":"Neuro Oncol"},{"issue":"2","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J Neurosurg"},{"issue":"1","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2011.7.JNS10238","article-title":"Insular glioma resection: assessment of patient morbidity, survival, and tumor progression","volume":"115","author":"Sanai","year":"2011","journal-title":"J Neurosurg"},{"issue":"1","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/not137","article-title":"Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma","volume":"16","author":"Chaichana","year":"2014","journal-title":"Neuro Oncol"},{"issue":"5","key":"bib19-20231011","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3171\/2014.7.JNS132449","article-title":"Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastomaversus extent of resection: predictors of survival after surgery for glioblastoma","volume":"121","author":"Grabowski","year":"2014","journal-title":"J Neurosurg"},{"issue":"2","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"issue":"2","key":"bib21-20231011","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3174\/ajnr.A4536","article-title":"Multimodal imaging in malignant brain tumors: enhancing the preoperative risk evaluation for motor deficits with a combined hybrid MRI-PET and navigated transcranial magnetic stimulation approach","volume":"37","author":"Neuschmelting","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.nicl.2016.11.022","article-title":"Functional MRI vs. navigated TMS to optimize M1 seed volume delineation for DTI tractography. A prospective study in patients with brain tumours adjacent to the corticospinal tract","volume":"13","author":"Weiss Lucas","year":"2017","journal-title":"Neuroimage Clin"},{"issue":"Suppl_1","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.2967\/jnumed.108.057174","article-title":"Assessing tumor response to therapy","volume":"50","author":"Weber","year":"2009","journal-title":"J Nucl Med"},{"issue":"3","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1667\/RR0787.1","article-title":"Growth laws in cancer: implications for radiotherapy","volume":"168","author":"Castorina","year":"2007","journal-title":"Radiat Res"},{"issue":"4","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/neuros\/nyx265","article-title":"The role of extent of resection in IDH1 wild-type or mutant low-grade gliomas","volume":"82","author":"Patel","year":"2018","journal-title":"Neurosurgery"},{"key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.wneu.2018.04.134","article-title":"Correlation between the residual tumor volume, extent of tumor resection, and O6-methylguanine DNA methyltransferase status in patients with glioblastoma","volume":"116","author":"Sharma","year":"2018","journal-title":"World Neurosurg"},{"issue":"1","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/neuros\/nyy049","article-title":"Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas","volume":"84","author":"Gessler","year":"2019","journal-title":"Clin Neurosurg"},{"issue":"5","key":"bib30-20231011","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3171\/2012.8.JNS12234","article-title":"Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival","volume":"117","author":"Orringer","year":"2012","journal-title":"J Neurosurg"},{"issue":"1-2","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.wneu.2014.05.006","article-title":"How much is enough? The question of extent of resection in glioblastoma multiforme","volume":"82","author":"Abd-El-Barr","year":"2014","journal-title":"World Neurosurg"},{"issue":"1-2","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.wneu.2014.01.019","article-title":"When gross total resection of a glioblastoma is possible, how much resection should be achieved","volume":"82","author":"Chaichana","year":"2014","journal-title":"World Neurosurg"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neurosurgery\/article-pdf\/88\/4\/E323\/36592864\/nyaa562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyaa562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:44Z","timestamp":1786121204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyaa562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyaa562","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]}}}